Texas stent developer nears $30M funding round; Myriad Genetics sues another Dx rival;

@FierceMedDev: 23andMe digs in as FDA wants test off the market. Story | Follow @FierceMedDev

@MarkHFierce: Please check out our latest issue of FierceDiagnostics, with lots of great industry news. Issue | Follow @MarkHFierce

> Texas cardiovascular stent maker Palmaz Scientific is close to completing a $30 million funding round. Story

> Echo Therapeutics ($ECTE) said it is on track for a 2013 fourth-quarter CE mark submission for its Symphony wireless continuous glucose monitoring system, following positive results from a multi-center trial. Item   

> California's CLR Medicals is recalling its Viscocel and Viscocel Plus ophthalmic devices after the FDA warned the company for marketing them without approval. More

> Diagnostics outfit Invitae intends to defend itself against a lawsuit from Myriad Genetics ($MYGN) over BRCA and MUTYH genetic tests. More

> Myco Medical expects a big revenue boost now that it will supply safety scalpels to medical device supplier novation. Story

Biotech News

@FierceBiotech: What would a Teva buyout mean for its R&D operation? Story | Follow @FierceBiotech

@JohnCFierce: GlaxoSmithKline dispatching R&D teams to new satellites in Cambridge, San Diego. Story | Follow @JohnCFierce

@DamianFierce: Sorin's expecting as much as 10% annual growth by 2018. Story | Follow @DamianFierce

@EmilyMFierce: Malaria cases soar in former rebel stronghold of Rutshuru, DRC. More | Follow @EmilyMFierce

> Korean CRO grabs failed cancer vaccine in $150M-max Jennerex buyout. Story

> Theraclone reels as feds deny funding for flu antibody. News

> Galapagos reaps $46M payday as GSK preps PhII study. Item

Pharma News

@FiercePharma: Bayer bids $2.4B for Xofigo partner Algeta in drive for cancer growth. Yesterday's story | Follow @FiercePharma

@EricPFierce: Finally, something that Teva can crow about. Treanda gets orphan status, extending its exclusivity. News | Follow @EricPFierce

@CarlyHFierce: Our annual Top Women in Biotech report is live! Special report | Follow @CarlyHFierce

> FDA bans second Wockhardt plant. News

> Adcock Ingram pleads merger essential for survival. Story

> Administration lauds Medicare drug discounts and wants more, more, more. Article

Drug Delivery News

> Study: Natural nanomaterials could support biodegradable drug delivery. Story

> Alnylam pockets $7M from Genzyme as RNAi program hums along. Article

> Aptar Pharma readies auto-injectable drug delivery tech. Report

> Focal Therapeutics' 3-D tissue marker for targeted cancer therapy reaches milestone. Story

> Arrowhead submits PhIIa application for hep B RNAi candidate. Article

> Supramolecular gel scaffold may support bone drug delivery. Item

Diagnostics News

> Veracyte boosts Dx revenue as CEO Anderson celebrates successful IPO. Story

> Canadian team relies on synchrotron to develop better prostate cancer Dx. Article

> In 23andMe's tussle with the FDA, 'diagnostic' is a contentious word. Story

> Oxford Immunotec, a TB Dx developer, performs well in its Nasdaq debut. Report

> Myriad ups companion Dx focus with BioMarin cancer drug collaboration. News

> BioMérieux team touts development of quicker sepsis Dx approach. Item

Biomarkers News

> Blood biomarker points to post-concussion cognitive problems. Report

> Regulus snags milestone in MS biomarker deal with Biogen. News

> Protein C4d linked to higher mortality rates in lung cancer patients. Story

> Women who test negative for BRCA mutation may still have higher breast cancer risk. Article

> Chemical fingerprint points to a likely biomarker for 'fast' form of Parkinson's. More

> Gentris opens biomarker shop in Shanghai. Item

Vaccines News

> FDA approves GSK's adjuvanted bird flu vaccine for stockpile. Report

> Novartis struggling to find vaccine acquisition targets for $5B war chest. Article

> Ranbaxy reportedly ready to sell vaccine unit. More

> Sanofi hunting for bolt-on vaccine deals. Story

> Value of Pentagon-backed vaccine plant questioned. News

> GAVI adds support for inactivated polio vaccine. Item

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

A COVID-19 antibody diagnostic developed through a joint venture between Mount Sinai Health System and RenalytixAI has been authorized by the FDA.

Researchers at Northwestern University have trained an AI algorithm to automatically detect the signs of COVID-19 on a basic X-ray of the lungs.

Hand-held ultrasound developer Butterfly Network is going public through a $1.5 billion acquisition deal backed by Glenview Capital.